The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The patient pathway to survival in second line DLBCL: improving access to CAR-T
In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, highlights that the survival outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who relapse after front-line therapy are often dependent on the availability of CAR T-cell therapy, namely axicabtagene ciloleucel, in the second line. Unfortunately, even when patients are eligible for CAR-T, there is a high attrition rate, and many will not receive the treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, there’s been a lot of changes in the second line pathway for patients with, particularly, high-risk relapsed diffuse large B-cell. So primary refractory to front line treatment or relapsed within a year. And the key thing there is the availability of second line CAR-T, in particular axi-cel, based on the ZUMA-7 study. And the key thing though, and there’s quite good data showing that, even when patients are eligible, quite often there’s a big attrition rate...
Well, there’s been a lot of changes in the second line pathway for patients with, particularly, high-risk relapsed diffuse large B-cell. So primary refractory to front line treatment or relapsed within a year. And the key thing there is the availability of second line CAR-T, in particular axi-cel, based on the ZUMA-7 study. And the key thing though, and there’s quite good data showing that, even when patients are eligible, quite often there’s a big attrition rate. In other words, patients don’t necessarily get to CAR-T, and it’s for a number of reasons. Some are unavoidable, you know, the disease is just too aggressive. But sometimes actually, it’s just simply perhaps a lack of awareness in the referring clinicians or perhaps also people look at the trial and think, okay, I can only refer those sorts of patients for CAR-T, but actually we know from real world data now that, you know, things like certain comorbidities or age in and of themselves may not be a barrier for second or even third line CAR-T.
So I think the message is for referrers to talk to a CAR-T physician or their local CAR-T infusion center to enable, you know, that that flow of patients, and it’s important to do it efficiently because these diseases do grow quite quickly, so we’ve got to make sure that patients get there in a timely way.
Read more...
Disclosures
Takeda, Roche, Beigene, Astra Zeneca, Abbvie, Sobi, Kite / Gilead, BMS, Pfizer, SecuraBio.
